$YCBD
cbdMD, Inc. Stock $ycbd

$ycbd Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-K Financial Statement

#000165495421013292 Filed on December 17, 2021

Income Statement

Concept	2021 Q3	2021	2020 Q3
Revenue	$9.793M	$44.48M	$11.70M
YoY Change	-16.3%	6.2%	34.72%
Cost Of Revenue	$4.051M	$14.50M	$5.334M
YoY Change	-24.06%	-6.57%	50.18%
Gross Profit	$5.743M	$29.99M	$6.366M
YoY Change	-9.79%	13.72%	24.02%
Gross Profit Margin	58.64%	67.41%	54.41%
Selling, General & Admin	$11.48M	$44.79M	$10.90M
YoY Change	5.31%	1.92%	1372.97%
% of Gross Profit	199.89%	149.39%	171.23%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$297.5K	$1.017M	$221.4K
YoY Change	34.41%	41.16%	1168.6%
% of Gross Profit	5.18%	3.39%	3.48%
Operating Expenses	$12.76M	$49.60M	$10.90M
YoY Change	17.05%	12.86%	6.89%
Operating Profit	-$7.013M	-$19.62M	-$4.531M
YoY Change	54.77%	11.57%	-10.48%
Interest Expense	$14.58K	$518.0K	-$32.49K
YoY Change	-144.88%	-491.82%	-102.03%
% of Operating Profit
Other Income/Expense, Net	$29.48K	$29.48K
YoY Change
Pretax Income	-$3.156M	-$24.29M	-$5.364M
YoY Change	-41.16%	-314.84%	-130.22%
Income Tax	-$130.0K	$895.0K	$895.0K
% Of Pretax Income
Net Earnings	-$2.917M	-$23.39M	-$6.259M
YoY Change	-53.39%	-285.64%	-156.02%
Net Earnings / Revenue	-29.79%	-52.6%	-53.49%
Basic Earnings Per Share		-$0.47
Diluted Earnings Per Share	-$52.64K	-$0.47	-$119.6K
COMMON SHARES
Basic Shares Outstanding	57.27M shares	54.94M shares
Diluted Shares Outstanding		54.94M shares

Balance Sheet

Concept	2021 Q3	2021	2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$26.44M	$27.44M	$15.10M
YoY Change	75.12%	81.74%	175.14%
Cash & Equivalents	$26.41M	$26.41M	$14.82M
Short-Term Investments	$33.35K	$1.033M	$276.5K
Other Short-Term Assets	$2.922M	$2.922M	$3.096M
YoY Change	-5.62%	-5.62%	-19.53%
Inventory	$5.573M	$5.022M	$4.892M
Prepaid Expenses
Receivables	$1.113M	$1.113M	$911.5K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$36.50M	$36.50M	$23.71M
YoY Change	53.94%	53.94%	50.62%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.562M	$8.177M	$3.183M
YoY Change	-19.54%	-18.52%	85.57%
Goodwill	$56.67M		$54.67M
YoY Change	3.66%
Intangibles	$23.00M		$21.64M
YoY Change	6.33%
Long-Term Investments
YoY Change
Other Assets	$529.6K	$529.6K	$790.7K
YoY Change	-33.02%	-33.02%	4.8%
Total Long-Term Assets	$88.38M	$88.38M	$87.13M
YoY Change	1.44%	1.44%	10.61%
TOTAL ASSETS
Total Short-Term Assets	$36.50M	$36.50M	$23.71M
Total Long-Term Assets	$88.38M	$88.38M	$87.13M
Total Assets	$124.9M	$124.9M	$110.8M
YoY Change	12.67%	12.67%	17.27%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.979M	$2.979M	$2.850M
YoY Change	4.51%	4.51%	-5.65%
Accrued Expenses	$2.728M	$3.879M	$3.884M
YoY Change	-29.77%	-0.13%	470.09%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$59.47K	$59.47K	$909.6K
YoY Change	-93.46%	-93.46%
Total Short-Term Liabilities	$6.917M	$6.917M	$7.689M
YoY Change	-10.04%	-10.04%	107.26%
LONG-TERM LIABILITIES
Long-Term Debt	$109.0K	$0.00	$264.4K
YoY Change	-58.78%	-100.0%
Other Long-Term Liabilities	$14.82M	$14.82M	$22.47M
YoY Change	-34.04%	-34.04%	-55.9%
Total Long-Term Liabilities	$14.82M	$14.82M	$23.97M
YoY Change	-38.16%	-35.76%	-52.96%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.917M	$6.917M	$7.689M
Total Long-Term Liabilities	$14.82M	$14.82M	$23.97M
Total Liabilities	$21.74M	$21.74M	$31.66M
YoY Change	-31.33%	-31.33%	-44.37%
SHAREHOLDERS EQUITY
Retained Earnings	-$73.34M		-$47.39M
YoY Change	54.76%
Common Stock	$57.78K		$52.13K
YoY Change	10.84%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$103.1M	$103.1M	$79.18M
YoY Change
Total Liabilities & Shareholders Equity	$124.9M	$124.9M	$110.8M
YoY Change	12.67%	12.67%	17.27%

Cashflow Statement

Concept	2021 Q3	2021	2020 Q3
OPERATING ACTIVITIES
Net Income	-$2.917M	-$23.39M	-$6.259M
YoY Change	-53.39%	-285.64%	-156.02%
Depreciation, Depletion And Amortization	$297.5K	$1.017M	$221.4K
YoY Change	34.41%	41.16%	1168.6%
Cash From Operating Activities	-$4.334M	-$14.09M	-$387.3K
YoY Change	1019.19%	32.15%	-93.87%
INVESTING ACTIVITIES
Capital Expenditures	-$30.44K	-$342.0K	$531.7K
YoY Change	-105.73%	-74.09%	-165.7%
Acquisitions
YoY Change
Other Investing Activities	-$2.000M	-$2.210M	-$250.0K
YoY Change	700.0%	784.0%	-188.63%
Cash From Investing Activities	-$2.030M	-$2.552M	$281.6K
YoY Change	-820.91%	62.54%	-153.43%
FINANCING ACTIVITIES
Cash Dividend Paid		$2.555M
YoY Change		596.36%
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	13.79M	$28.23M	-76.07K
YoY Change	-18230.7%	26.21%	-19.03%
NET CHANGE
Cash From Operating Activities	-4.334M	-$14.09M	-387.3K
Cash From Investing Activities	-2.030M	-$2.552M	281.6K
Cash From Financing Activities	13.79M	$28.23M	-76.07K
Net Change In Cash	7.427M	$11.59M	-181.7K
YoY Change	-4188.19%	14.33%	-97.38%
FREE CASH FLOW
Cash From Operating Activities	-$4.334M	-$14.09M	-$387.3K
Capital Expenditures	-$30.44K	-$342.0K	$531.7K
Free Cash Flow	-$4.304M	-$13.75M	-$918.9K
YoY Change	368.35%	47.16%	-83.33%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	57805007	shares
CY2021Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	26411424	USD
CY2020Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	14824644	USD
CY2021Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	1113372	USD
CY2020Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	911482	USD
CY2021Q3	ycbd	Disposal Group Including Discontinued Operation Accounts Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNet	10967	USD
CY2020Q3	ycbd	Disposal Group Including Discontinued Operation Accounts Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNet	447134	USD
CY2021Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	33351	USD
CY2020Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	26472	USD
CY2021Q3	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	1000000	USD
CY2020Q3	us-gaap	Other Investments And Securities At Cost OtherInvestmentsAndSecuritiesAtCost	250000	USD
CY2021Q3	us-gaap	Inventory Gross InventoryGross	5021867	USD
CY2020Q3	us-gaap	Inventory Gross InventoryGross	4603360	USD
CY2021Q3	ycbd	Prepaid Inventory Current PrepaidInventoryCurrent	551519	USD
CY2020Q3	ycbd	Prepaid Inventory Current PrepaidInventoryCurrent	288178	USD
CY2021Q3	ycbd	Prepaid Software PrepaidSoftware	0	USD
CY2020Q3	ycbd	Prepaid Software PrepaidSoftware	174308	USD
CY2021Q3	ycbd	Prepaid Sponsorship PrepaidSponsorship	1212682	USD
CY2020Q3	ycbd	Prepaid Sponsorship PrepaidSponsorship	1203300	USD
CY2021Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1147178	USD
CY2020Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	983374	USD
CY2021Q3	us-gaap	Assets Current AssetsCurrent	36502360	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	23712252	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2561574	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3183487	USD
CY2021Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5614960	USD
CY2020Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6851357	USD
CY2021Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	529583	USD
CY2020Q3	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	790708	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23003929	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	21635000	USD
CY2021Q3	us-gaap	Goodwill Goodwill	56670970	USD
CY2020Q3	us-gaap	Goodwill Goodwill	54669997	USD
CY2021Q3	us-gaap	Other Assets OtherAssets	88381016	USD
CY2020Q3	us-gaap	Other Assets OtherAssets	87130549	USD
CY2021Q3	us-gaap	Assets Assets	124883376	USD
CY2020Q3	us-gaap	Assets Assets	110842801	USD
CY2021Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2978914	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2850421	USD
CY2021Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2727612	USD
CY2020Q3	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2769920	USD
CY2021Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1151150	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1159098	USD
CY2021Q3	ycbd	Paycheck Protection Program Loan Current Portion PaycheckProtectionProgramLoanCurrentPortion	0	USD
CY2020Q3	ycbd	Paycheck Protection Program Loan Current Portion PaycheckProtectionProgramLoanCurrentPortion	854000	USD
CY2021Q3	us-gaap	Notes Payable Current NotesPayableCurrent	59470	USD
CY2020Q3	us-gaap	Notes Payable Current NotesPayableCurrent	55639	USD
CY2021Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6917146	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7689078	USD
CY2021Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	108985	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	264367	USD
CY2021Q3	ycbd	Paycheck Protection Program Loan PaycheckProtectionProgramLoan	0	USD
CY2020Q3	ycbd	Paycheck Protection Program Loan PaycheckProtectionProgramLoan	602100	USD
CY2021Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4859058	USD
CY2020Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6010208	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	9856000	USD
CY2020Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	16200000	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2020Q3	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	895000	USD
CY2021Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	14824043	USD
CY2020Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	23971675	USD
CY2021Q3	us-gaap	Liabilities Liabilities	21741189	USD
CY2020Q3	us-gaap	Liabilities Liabilities	31660753	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	5000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	500000	shares
CY2021Q3	us-gaap	Preferred Stock Value PreferredStockValue	5000	USD
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	500	USD
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57783340	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52130870	shares
CY2021Q3	us-gaap	Common Stock Value CommonStockValue	57783	USD
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	52131	USD
CY2021Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	176417269	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	126517784	USD
CY2021Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-73337865	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-47388367	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	103142187	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	79182048	USD
CY2021Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124883376	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	110842801	USD
CY2021	ycbd	Sales Revenue Gross SalesRevenueGross	47332085	USD
CY2020	ycbd	Sales Revenue Gross SalesRevenueGross	43172778	USD
CY2021	ycbd	Sales Allowances SalesAllowances	2851322	USD
CY2020	ycbd	Sales Allowances SalesAllowances	1289044	USD
CY2021	us-gaap	Revenues Revenues	44480763	USD
CY2020	us-gaap	Revenues Revenues	41883734	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	14495063	USD
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	15514727	USD
CY2021	us-gaap	Gross Profit GrossProfit	29985700	USD
CY2020	us-gaap	Gross Profit GrossProfit	26369007	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	49601690	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	43950862	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-19615990	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-17581855	USD
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	546878	USD
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-932066	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1466113	USD
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2021	ycbd	Increase Decrease Of Contingent Liability IncreaseDecreaseOfContingentLiability	-6687439	USD
CY2020	ycbd	Increase Decrease Of Contingent Liability IncreaseDecreaseOfContingentLiability	29780000	USD
CY2021	ycbd	Dividend Preferred DividendPreferred	-2554609	USD
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	97720	USD
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	338400	USD
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	670580	USD
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	29479	USD
CY2020	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	USD
CY2021	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-28930	USD
CY2020	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	39877	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-24289889	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	11305956	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	895000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1345300	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-23394889	USD
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	12651256	USD
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	0	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-48983	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23394889	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	12602273	USD
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2554609	USD
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	366850	USD
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25949498	USD
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	12235423	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.47
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	54938128	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	44140360	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45171674	shares
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23394889	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	12602273	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-23394889	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12602273	USD
CY2020	ycbd	Dividend Preferred DividendPreferred	-366850	USD
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-25949498	USD
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	12235423	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-23394889	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	12602273	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	1298106	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	1900194	USD
CY2021	us-gaap	Restricted Stock Expense RestrictedStockExpense	1626613	USD
CY2020	us-gaap	Restricted Stock Expense RestrictedStockExpense	138000	USD
CY2021	ycbd	Marketing Stock Amortization MarketingStockAmortization	871390	USD
CY2020	ycbd	Marketing Stock Amortization MarketingStockAmortization	0	USD
CY2020	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	233372	USD
CY2021	ycbd	Discontinued Operations Asset Impairment Charges DiscontinuedOperationsAssetImpairmentCharges	0	USD
CY2020	ycbd	Discontinued Operations Asset Impairment Charges DiscontinuedOperationsAssetImpairmentCharges	45783	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1017408	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	720755	USD
CY2021	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	0	USD
CY2020	us-gaap	Other Than Temporary Impairment Losses Investments Availableforsale Securities OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities	760000	USD
CY2021	ycbd	Increase Decrease In Contingent Liability IncreaseDecreaseInContingentLiability	6687439	USD
CY2020	ycbd	Increase Decrease In Contingent Liability IncreaseDecreaseInContingentLiability	-29780000	USD
CY2021	ycbd	Realized And Unrealized Loss Of Marketable And Other Securities RealizedAndUnrealizedLossOfMarketableAndOtherSecurities	-546878	USD
CY2020	ycbd	Deferred Issuance Costs DeferredIssuanceCosts	62197	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28232226	USD
CY2020	ycbd	Realized And Unrealized Loss Of Marketable And Other Securities RealizedAndUnrealizedLossOfMarketableAndOtherSecurities	172066	USD
CY2021	ycbd	Merchant Reserve Settlement MerchantReserveSettlement	0	USD
CY2020	ycbd	Merchant Reserve Settlement MerchantReserveSettlement	132657	USD
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	196896	USD
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	489381	USD
CY2021	ycbd	Extinguishment Of Paycheck Protection Program Loan ExtinguishmentOfPaycheckProtectionProgramLoan	-1466113	USD
CY2020	ycbd	Extinguishment Of Paycheck Protection Program Loan ExtinguishmentOfPaycheckProtectionProgramLoan	0	USD
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1236397	USD
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1180213	USD
CY2021	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	-183735	USD
CY2020	us-gaap	Increase Decrease In Accounts And Other Receivables IncreaseDecreaseInAccountsAndOtherReceivables	514352	USD
CY2021	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	261125	USD
CY2020	us-gaap	Increase Decrease In Deposits IncreaseDecreaseInDeposits	-938112	USD
CY2021	ycbd	Increase Decrease Merchant Reserve Settlement IncreaseDecreaseMerchantReserveSettlement	0	USD
CY2020	ycbd	Increase Decrease Merchant Reserve Settlement IncreaseDecreaseMerchantReserveSettlement	386912	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1009192	USD
CY2020	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-535146	USD
CY2021	ycbd	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	-263341	USD
CY2020	ycbd	Increase Decrease In Prepaid Inventory IncreaseDecreaseInPrepaidInventory	615280	USD
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	525670	USD
CY2020	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	645796	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-104422	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1479189	USD
CY2021	ycbd	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1159097	USD
CY2020	ycbd	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1045285	USD
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	3723	USD
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	37802	USD
CY2021	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	436167	USD
CY2020	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	587083	USD
CY2021	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-895000	USD
CY2020	us-gaap	Increase Decrease In Deferred Income Taxes IncreaseDecreaseInDeferredIncomeTaxes	-1345300	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14093433	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10664335	USD
CY2021	ycbd	Proceeds From Sale Of Other Investment Securities ProceedsFromSaleOfOtherInvestmentSecurities	540000	USD
CY2020	ycbd	Proceeds From Sale Of Other Investment Securities ProceedsFromSaleOfOtherInvestmentSecurities	0	USD
CY2021	ycbd	Purchase Of Other Investment Securities PurchaseOfOtherInvestmentSecurities	-750000	USD
CY2020	ycbd	Purchase Of Other Investment Securities PurchaseOfOtherInvestmentSecurities	-250000	USD
CY2021	ycbd	Purchase Of Directcbdonline Com PurchaseOfDirectcbdonlineCom	-2000000	USD
CY2020	ycbd	Purchase Of Directcbdonline Com PurchaseOfDirectcbdonlineCom	0	USD
CY2021	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	342013	USD
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	1320095	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2552013	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1570095	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	16766106	USD
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	30938386	USD
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	4421928	USD
CY2021	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	0	USD
CY2020	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	1456100	USD
CY2021	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	-151551	USD
CY2020	us-gaap	Increase Decrease In Notes Payable Current IncreaseDecreaseInNotesPayableCurrent	29629	USD
CY2021	us-gaap	Payments Of Dividends PaymentsOfDividends	2554609	USD
CY2020	us-gaap	Payments Of Dividends PaymentsOfDividends	366850	USD
CY2021	ycbd	Deferred Issuance Costs DeferredIssuanceCosts	0	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	85719646	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	11426200	USD
CY2019Q4	ycbd	Preferred Stock Issued During Period Value New Issues PreferredStockIssuedDuringPeriodValueNewIssues	4421928	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	627648	USD
CY2021Q1	ycbd	Issuance Of Restricted Stock For Share Based Compensation Amount IssuanceOfRestrictedStockForShareBasedCompensationAmount	1181828	USD
CY2021Q1	ycbd	Preferred Dividend PreferredDividend	-560279	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12510474	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	85884569	USD
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1472600	USD
CY2021Q2	ycbd	Issuance Of Options For Share Based Compensation IssuanceOfOptionsForShareBasedCompensation	355565	USD
CY2021Q2	ycbd	Issuance Of Restricted Stock For Share Based Compensation Amount IssuanceOfRestrictedStockForShareBasedCompensationAmount	590291	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22369110	USD
CY2021	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	11586780	USD
CY2020	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	10134680	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14824644	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4689966	USD
CY2021Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26411424	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	28930	USD
CY2020	us-gaap	Interest Paid Net InterestPaidNet	33693	USD
CY2021	ycbd	Issuance Of Contingent Earnout Shares IssuanceOfContingentEarnoutShares	13520000	USD
CY2020	ycbd	Issuance Of Contingent Earnout Shares IssuanceOfContingentEarnoutShares	4620000	USD
CY2021	ycbd	Warrants Issued To Representative WarrantsIssuedToRepresentative	499587	USD
CY2020	ycbd	Warrants Issued To Representative WarrantsIssuedToRepresentative	524113	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	79182048	USD
CY2020Q4	ycbd	Preferred Stock Issued During Period Value New Issues PreferredStockIssuedDuringPeriodValueNewIssues	15798115	USD
CY2020Q4	ycbd	Issuance Of Options For Share Based Compensation IssuanceOfOptionsForShareBasedCompensation	219875	USD
CY2020Q4	ycbd	Stock Issued Issuance Costs StockIssuedIssuanceCosts	0	USD
CY2020Q4	ycbd	Issuance Of Restricted Stock For Share Based Compensation IssuanceOfRestrictedStockForShareBasedCompensation	15279	USD
CY2020Q4	ycbd	Preferred Dividend PreferredDividend	-100050	USD
CY2020Q4	us-gaap	Net Income Loss NetIncomeLoss	-9395621	USD
CY2021Q2	ycbd	Preferred Dividend PreferredDividend	-560281	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	1537288	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	89280032	USD
CY2021Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	922500	USD
CY2021Q3	ycbd	Issuance Of Preferred Stock IssuanceOfPreferredStock	15142571	USD
CY2021Q3	ycbd	Issuance Of Options For Share Based Compensation IssuanceOfOptionsForShareBasedCompensation	493000	USD
CY2021Q3	ycbd	Issuance Of Restricted Stock For Share Based Compensation IssuanceOfRestrictedStockForShareBasedCompensation	479899	USD
CY2021Q3	ycbd	Acquisition Of Dco AcquisitionOfDco	1184265	USD
CY2021Q3	ycbd	Preferred Dividend PreferredDividend	-1333999	USD
CY2021Q3	us-gaap	Net Income Loss NetIncomeLoss	-2917082	USD
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	103142187	USD
CY2019Q3	us-gaap	Stockholders Equity StockholdersEquity	37603984	USD
CY2019Q4	ycbd	Issuance Of Options For Share Based Compensation IssuanceOfOptionsForShareBasedCompensation	542574	USD
CY2019Q4	ycbd	Stock Issued Issuance Costs StockIssuedIssuanceCosts	-31757	USD
CY2019Q4	ycbd	Issuance Of Restricted Stock For Share Based Compensation IssuanceOfRestrictedStockForShareBasedCompensation	138000	USD
CY2019Q4	ycbd	Preferred Dividend PreferredDividend	-66734	USD
CY2019Q4	ycbd	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Change On Net Income Loss NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfChangeOnNetIncomeLoss	-13528	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	12929763	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	55524230	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	21391757	USD
CY2020Q1	ycbd	Exercise Of Options For Share Based Compensation ExerciseOfOptionsForShareBasedCompensation	429651	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	28250	USD
CY2020Q1	ycbd	Preferred Dividend PreferredDividend	-100016	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	14883772	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	92157644	USD
CY2020Q2	ycbd	Issuance Of Options For Share Based Compensation IssuanceOfOptionsForShareBasedCompensation	419045	USD
CY2020Q2	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	56200	USD
CY2020Q2	ycbd	Preferred Dividend PreferredDividend	-100050	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-8952702	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	83580137	USD
CY2020Q3	ycbd	Issuance Of Options For Share Based Compensation IssuanceOfOptionsForShareBasedCompensation	508923	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	1451600	USD
CY2020Q3	ycbd	Preferred Dividend PreferredDividend	-100050	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	-6258562	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	79182048	USD
CY2021	ycbd	Organization And Summary Of Significant Accounting Policiestextblock OrganizationAndSummaryOfSignificantAccountingPoliciestextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>NOTE 1 </strong><strong>–</strong><strong> </strong><strong>ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Organization</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Nature</strong><strong> </strong><strong>of Business</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">cbdMD, Inc. ("cbdMD", "we", "us", “our”, or the “Company”) is a North Carolina corporation formed on March 17, 2015 as Level Beauty Group, Inc. In November 2016 we changed the name of the Company to Level Brands, Inc. and on May 1, 2019 we changed the name of our Company to cbdMD, Inc. We operate from our offices located in Charlotte, North Carolina. Our fiscal year end is established as September 30.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 20, 2018 (the “Closing Date”), the Company, and its newly organized wholly owned subsidiaries AcqCo, LLC and cbdMD LLC (“CBDI”), completed a two-step merger (the “Mergers”) with Cure Based Development, LLC, a Nevada limited liability company (“Cure Based Development”). Upon completion of the Mergers, CBDI survived and operates the prior business of Cure Based Development. As consideration for the Mergers, the Company had a contractual obligation, after approval by our shareholders, to issue 15,250,000 shares of our common stock to the members of Cure Based Development, of which unrestricted voting rights to 8,750,000 of the shares vest over a five-year period and are subject to a voting proxy agreement, as well as to issue another 15,250,000 shares of our common stock (the “Earnout Shares”) in the future upon certain earnout goals being achieved within five years from the closing of the Mergers. The Company’s shareholders approved the issuance of the 15,250,000 shares of common stock in April 2019 and these shares were issued to members of Cure Based Development on April 19, 2019. In April 2019, our shareholders also approved the possible issuance of the Earnout Shares. The first marking period for the earnout was December 31, 2019 and based on measurement criteria, 5,127,792 Earnout Shares had been earned and were issued on February 27, 2020. The sole member of Cure Based Development at the closing of the Mergers was CBD Holding LLC (“CBDH”). In February 2020, in connection with its liquidation, CBDH distributed the rights to the Earnout Shares (the “Earnout Rights”) to its members based upon the members’ pro pro-rata ownership interest in CBDH. Members of CBDH at the time of its liquidation and this distribution included affiliates of Martin A. Sumichrast and R. Scott Coffman, directors and executive officers of cbdMD. A second marking period for the earnout ended December 31, 2020 and based on measurement criteria an additional 3,348,520 Earnout Shares had been earned and were issued on March 8, 2021. The first quarter of the third marking period ended on March 31, 2021 and based on the measurement criteria an additional 562,278 Earnout Shares had been earned and issued in May of 2021. The second quarter of the third marking period ended on June 30, 2021 and based on the measurement criteria an additional 503,275 Earnout Shares had been earned and issued in August of 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company owns and operates the nationally recognized CBD (cannabidiol) brands cbdMD, Paw CBD and cbdMD Botanicals. The Company sources cannabinoids, including CBD, which are extracted from non-GMO hemp grown on farms in the United States. CBD and other hemp-derived cannabinoids are natural substances produced from the hemp plant and the products manufactured by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the third quarter of fiscal 2019 cbdMD launched its new CBD pet brand, Paw CBD. Following the initial positive response to the brand from retailers and consumers, cbdMD, Inc. organized Paw CBD, Inc. (“Paw CBD”) as a separate wholly owned subsidiary on October 22, 2019, to take advantage of its early mover status in the CBD animal health industry. On March 15, 2021 cbdMD formed a new wholly owned subsidiary, cbdMD Therapeutics, LLC (“Therapeutics”) for the purposes of isolating and quantifying the Company’s ongoing investments in science related to its existing and future products, including research and development activities for therapeutic applications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements of cbdMD have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report filed with the SEC on Form 10-K for the year ended September 30, 2020 (“2020 10-K”) as filed with the SEC on December 22, 2020. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of consolidated financial position and the consolidated results of operations for the interim periods presented have been reflected herein.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Principles</strong><strong> </strong><strong>of</strong><strong> </strong><strong>Consolidation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries CBDI, Paw CBD and Therapeutics. All material intercompany transactions and balances have been eliminated in consolidation.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Use of Estimates</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company's consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying consolidated financial statements include, but are not limited to, allowances for doubtful accounts, inventory valuation reserves, expected sales returns and allowances, certain assumptions related to the valuation of investments other securities, acquired intangible and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities, contingent liability and, hence consideration for the Mergers is a material estimate. Actual results could differ from these estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 11, 2020, the World Health Organization declared the COVID-19 outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the United States, federal, state and local governments throughout the country have imposed varying degrees of restriction on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. We continue to monitor the waning trends on infection rates and are cautiously optimistic future impacts to the business environment will be minimal.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cash</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Cash</strong><strong> </strong><strong>Equivalents</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">For financial statements purposes, the Company considers all highly liquid investments with a maturity of less than three months when purchased to be cash equivalents.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Accounts</strong><strong> </strong><strong>Receivable</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Accounts</strong><strong> </strong><strong>Receivable</strong><strong> </strong><strong>Other</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Accounts receivables are stated at cost less an allowance for doubtful accounts, if applicable. Credit is extended to customers after an evaluation of the customer’s financial condition, and generally collateral is not required as a condition of credit extension. Management’s determination of the allowance for doubtful accounts is based on an evaluation of the receivables, past experience, current economic conditions, and other risks inherent in the receivables portfolio. As of September 30, 2021 and September 30, 2020, we had an allowance for doubtful accounts of $3,633 and $20,664, respectively.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Merchant</strong><strong> </strong><strong>Receivable</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Reserve</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company primarily sells its products through the internet and has an arrangement to process customer payments with multiple third-party payment processors. The Company pay a fee between 2.5% and 5.0% of the transaction amounts processed. Pursuant to this agreement, there can be a waiting period between 2 to 5 days prior to reimbursement to the Company, as well as a calculated reserve which some payment processors hold back. Fees and reserves can change periodically with notice from the processors. At September 30, 2021, the receivable from payment processors included approximately $231,257 for the waiting period amount and is recorded as accounts receivable in the accompanying consolidated balance sheet.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Inventory</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory is stated at the lower of cost or net realizable value with cost being determined on a weighted average basis. The cost of inventory includes product cost, freight-in, and production fill and labor (portions of which we outsource to third party manufacturers). Write-offs of potentially slow moving or damaged inventory are recorded based on management’s analysis of inventory levels, forecasted future sales volume and pricing and through specific identification of obsolete or damaged products. We assess inventory quarterly for slow moving products and potential impairments and at a minimum perform a physical inventory count annually near fiscal year end.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Customer</strong><strong> </strong><strong>Deposits</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Customer deposits consist of payments received in advance of revenue recognition. Revenue is recognized as revenue recognition criteria are met.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Property</strong><strong> </strong><strong>and</strong><strong> </strong><strong>Equipment</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Property and equipment items are stated at cost less accumulated depreciation. Expenditures for routine maintenance and repairs are charged to operations as incurred. Depreciation is charged to expense over the estimated useful lives of the assets using the straight-line method. Generally, the useful lives are five years for manufacturing equipment and automobiles and three years for software, computer, and furniture and equipment. The useful life for leasehold improvements are over the term of the lease or expected life of the asset, whichever is less. The cost and accumulated depreciation of property are eliminated from the accounts upon disposal, and any resulting gain or loss is included in the consolidated statements of operations for the applicable period. Long-lived assets held and used by the Company are reviewed for impairment whenever changes in circumstance indicate the carrying value of an asset may not be recoverable.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Fair Value Accounting</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company utilizes accounting standards for fair value, which include the definition of fair value, the framework for measuring fair value, and disclosures about fair value measurements. Fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, fair value accounting standards establish a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions about market participant assumptions (unobservable inputs classified within Level 3 of the hierarchy).</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Level 1 inputs utilize quoted prices in active markets for identical assets or liabilities that the Company has the ability to access. Level 2 inputs are inputs other than quoted prices included in Level 1 that are directly or indirectly observable for the asset or liability. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability. Level 3 inputs are unobservable inputs for the asset or liability, which are based on an entity’s own assumptions, as there is little, if any, observable market activity. In instances where the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">When the Company records an investment in marketable securities the carrying value is recorded at fair value. Any changes in fair value for marketable securities during a given period will be recorded as an unrealized gain or loss in the consolidated statement of operations. For investment other securities without a readily determinable fair value, the Company may elect to estimate its fair value at cost less impairment plus or minus changes resulting from observable price changes.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Goodwill</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Goodwill represents the excess of cost of an acquired business over the fair value of the identifiable tangible and intangible assets acquired and liabilities assumed in a business combination. Identifiable intangible assets acquired in business combinations are recorded based on their fair values at the date of acquisition. Goodwill is not subject to amortization but must be evaluated for impairment annually. The Company tests for goodwill impairment annually or whenever events occur or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying amount.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In performing a goodwill test, the Company performs a qualitative evaluation and if necessary, a quantitative evaluation. Factors considered in the qualitative test include specific operating results as well as new events and circumstances impacting the operations or cash flows of the business acquired. For the quantitative test, the Company assesses goodwill for impairment by comparing the carrying value of the business to the respective fair value. The Company determines the fair value of its acquired business using a combination of income-based and market-based approaches and incorporates assumptions it believes market participants would utilize. The income-based approach utilizes discounted cash flows while the market-based approach utilizes market multiples. These approaches are dependent upon internally developed forecasts that are based upon annual budgets and longer-range strategic plans. The Company uses discount rates that are commensurate with the risks and uncertainty inherent in the respective acquired business and in the internally developed forecasts. The Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on its business to determine if a circumstance could trigger an impairment loss, and, at this time and based on the information presently known, does not believe that it is more likely than not that an impairment loss has been incurred.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Intangible</strong><strong> </strong><strong>Assets</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company's intangible assets consist of trademarks and other intellectual property, all of which are accounted for in accordance with Accounting Standards Codification (ASC) Topic 350, <em>Intangibles </em><em>–</em><em> </em><em>Goodwill and Other</em>. The Company employs the non-amortization approach to account for purchased intangible assets having indefinite lives. Under the non-amortization approach, intangible assets having indefinite lives are not amortized into the results of operations, but instead are reviewed annually or more frequently if events or changes in circumstances indicate that the assets might be impaired, to assess whether their fair value exceeds their carrying value. We perform an annual impairment analysis as of August 1 of each fiscal year on the indefinite-lived intangible assets following the steps laid out in ASC 350-30-35-18. Our annual impairment analysis includes a qualitative assessment to determine if it is necessary to perform the quantitative impairment test. In performing a qualitative assessment, we review events and circumstances that could affect the significant inputs used to determine if the fair value is less than the carrying value of the intangible assets. If a quantitative analysis is necessary, we would analyze various aspects including revenues from the business, associated with the intangible assets. In addition, intangible assets will be tested on an interim basis if an event or circumstance indicates that it is more likely than not that an impairment loss has been incurred. In addition, the Company has analyzed a variety of factors in light of the known impact to date of the COVID-19 pandemic on its business to determine if a circumstance could trigger an impairment loss, and, at this time there have been no events identified that would trigger an impairment.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Contingent</strong><strong> </strong><strong>Liability</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A significant component of the purchase price consideration for the Company’s acquisition of Cure Based Development includes a fixed number of future shares to be issued as well as a variable number of future shares to be issued based upon the post-acquisition entity reaching certain specified future revenue targets, as further described in Note 6. The Company made a determination of the fair value of the contingent liabilities as part of the valuation of the assets acquired and liabilities assumed in the business combination.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company recognized both the fixed number of shares to be issued, and the variable number of shares to be potentially issued, as contingent liabilities on its consolidated balance sheets. These contingent liabilities were recorded at fair value upon the acquisition date and are remeasured quarterly based on the reassessed fair value as of the end of that quarterly reporting period. Additionally, as the fixed shares were issued on April 19, 2019, the value of the shares at that time, in the amount of $53,215,163, was reclassified from contingent liability to additional paid in capital on the consolidated balance sheet. The first marking period for the Earnout Shares was December 31, 2019 and based on measurement criteria, 5,127,792 shares were issued on February 27, 2020. The value of the issued Earnout Shares as of February 27, 2020 was $4,620,000 and the decrease in value of $6,924,503 from December 31, 2019 related to those shares was recorded in the Statement of Operations for the three months ended March 31, 2020. Additionally, as the 5,127,792 Earnout Shares were issued on February 27, 2020, the value of the shares in the amount of $4,620,000 was reclassified from the contingent liability to additional paid in capital on the consolidated balance sheet. The second marking period for the Earnout Shares ended December 31, 2020 and based on measurement criteria, 3,348,520 Earnout Shares were issued on March 8, 2021. The second marking period shares increased in value by $3,100,012 during the quarter through the time of issuance and had a value of $11,271,000, which was reclassified from the contingent liability to additional paid in capital on the consolidated balance sheet. The first quarter of the third marking period ended on March 31, 2021 and based on the measurement criteria an additional 562,278 Earnout Shares had been earned and issued in May of 2021. These shares deceased in value by $522,104 during the quarter through the time of issuance and had a value of $1,329,000 which was reclassified from the contingent liability to additional paid in capital on the consolidated balance sheet. The second quarter of the third marking period ended on June 30, 2021 and based on the measurement criteria an additional 503,275 Earnout Shares had been earned and issued in August of 2021. These shares deceased in value by $222,442 during the quarter through the time of issuance and had a value of $920,000 which was reclassified from the contingent liability to additional paid in capital on the consolidated balance sheet.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A component of the purchase price consideration for the Company’s acquisition of Twenty Two Capital, LLC (“Twenty Two”) includes 200,000 of future shares (“Twenty Two Earnout Shares”) to be issued upon the post-acquisition entity reaching certain specified revenue targets, as further described in Note 6. Under GAAP, the Company is required to record a non-cash contingent liability associated with the Twenty Two Earnout Shares and at the date of the acquisition, recorded a total contingent liability of $488,561. Under GAAP, the Company is obligated to reassess the obligations associated with the Twenty Two Earnout Shares on a quarterly basis and, in the event the Company’s estimate of the fair value of the contingent consideration changes, will record increases or decreases in the fair value as an adjustment to earnings. In particular, changes in the market price of the Company’s common stock, which is one of the inputs used in determining the amount of the non-cash contingent liability, will result in increases or decreases in this liability and positively or negatively impact the Company’s net loss or profit for the period. At September 30, 2021, the Company recorded a decrease in value of the contingent liability of $73,561 related to a decrease in the market price of its common stock, which adjusted the total contingent liability related to the DCO Earnout Shares to $416,000.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Paycheck</strong><strong> </strong><strong>Protection</strong><strong> </strong><strong>Program</strong><strong> </strong><strong>Loan</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On April 27, 2020, we received a loan in the principal amount of $1,456,100 (the “SBA Loan”) in consideration of a Promissory Note, under the Paycheck Protection Program (“PPP”), which was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll as it navigates its business with a focus on returning to normal operations. The term of the Promissory Note is two years, though it may be payable sooner in connection with an event of default under the Promissory Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company used the SBA Loan for qualifying expenses in accordance with the terms of the CARES Act. The Company filed for forgiveness under the terms of the SBA loan and on May 17, 2021 it received notice from the SBA that the loan had been forgiven. The Company subsequently booked $1,466,113 of gain for unpaid principal and accrued interest. This gain is reflected within Other Income (Expenses) on the consolidated statements of operations.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Revenue</strong><strong> </strong><strong>Recognition</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Under ASC 606, <em>Revenue from Contracts with Customers, </em>the Company recognizes revenues when its customer obtains control of promised goods or services, in an amount that reflects the consideration which it expects to receive in exchange for those goods. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenues when (or as) we satisfy the performance obligation. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Performance Obligations</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A performance obligation is a promise in a contract to transfer a distinct good or service to a customer. The Company meets that obligation when it has shipped products which have been ordered by the customer. The Company has reviewed its various revenue streams for its other contracts under the five-step approach. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Allocation</em><em> </em><em>of</em><em> </em><em>Transaction</em><em> </em><em>Price</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the Company’s current business model, it does not have contracts with customers which have multiple elements as revenue is driven purely by online product sales or purchase order-based product sales. However, at times in the past, the Company has entered into contracts with customers wherein there were multiple elements that may have disparate revenue recognition patterns. In such instances, the Company must allocate the total transaction price to these various elements. This is achieved by estimating the standalone selling price of each element, which is the price at which we sell a promised good or service separately to a customer.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Revenue</em><em> </em><em>Recognition</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company records revenue from the sale of its products when risk of loss and title to the product are transferred to the customer, which is upon shipping (and is typically FOB shipping) which is when our performance obligation is met. Net sales are comprised of gross revenues less product returns, trade discounts and customer allowances, which include costs associated with off-invoice mark-downs and other price reductions, as well as trade promotions. These incentive costs are recognized at the later of the date on which the Company recognizes the related revenue or the date on which the Company offers the incentive. The Company currently offers a 60-day, money back guarantee.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><em>Disaggregated</em><em> </em><em>Revenue</em></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s product revenue is generated primarily through two sales channels, E-commerce sales (formerly referred to as consumer sales) and wholesale sales. The Company believes that these categories appropriately reflect how the nature, amount, timing and uncertainty of revenue and cash flows are impacted by economic factors.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">A description of the Company’s principal revenue generating activities are as follows:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;font-size:10pt;font-variant:normal;font-weight:normal;font-style:normal;text-align:justify;margin-left:auto;line-height:normal;margin-right:auto;width:100%"><tbody><tr style="height:15px"><td style="width:4%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:4%;vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;">E-commerce sales - consumer products sold through the Company’s online and telephonic channels. Revenue is recognized when control of the merchandise is transferred to the customer, which generally occurs upon shipment. Payment is typically due prior to the date of shipment; and</td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px;text-indent:30px"> </p></td><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><span style="font-family:symbol">-</span></p></td><td style="vertical-align:top;">Wholesale sales - products sold to the Company’s wholesale customers for subsequent resale. Revenue is recognized when control of the goods is transferred to the customer, in accordance with the terms of the applicable agreement. Payment terms vary and can typically be 30 days from the date control over the product is transferred to the customer</td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The following table represents a disaggregation of revenue by sales channel:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fiscal 2021</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>% of total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>Fiscal 2020</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>% of total</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Wholesale sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,572,807</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">26.0</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">11,377,238</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">27.2</td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">E-commerce sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">32,907,956</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">74.0</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">30,456,496</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">72.8</td><td style="PADDING-BOTTOM: 1px;width:1%;vertical-align:bottom;white-space: nowrap;">%</td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total Net Sales</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">44,480,763</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:right;">41,833,734</td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;width:9%;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="PADDING-BOTTOM: 1px;width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Contract assets represent unbilled receivables and are presented within accounts receivable, net on the consolidated balance sheets. Contract liabilities represent unearned revenues and are presented as deferred revenue or customer deposits on the consolidated balance sheets. The Company has no material contract assets nor contract liabilities at September 30, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Cost of Sales</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company’s cost of sales includes costs associated with distribution, fill and labor expense, components, manufacturing overhead, third-party providers, and outbound freight for the Company’s products sales. For the Company’s product sales, cost of sales also includes the cost of refurbishing products returned by customers that will be offered for resale, if any, and the cost of inventory write-downs associated with adjustments of held inventories to their net realizable value. These expenses are reflected in the Company’s consolidated statements of operations when the product is sold and net sales revenues are recognized or, in the case of inventory write-downs, when circumstances indicate that the carrying value of inventories is in excess of their net realizable value.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Advertising Costs</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company expenses all costs of advertising and related marketing and promotional costs as incurred. The Company incurred approximately $15,835,139 and $9,946,755 in advertising and marketing and promotional costs included in operating expenses during the years ended September 30, 2021 and 2020 respectively. The Company believes driving its advertising aids in brand awareness and is critical to maintain brand recognition. We are constantly evaluating advertising methods and costs and working to drive down our cost of customer acquisition. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Income</strong><strong> </strong><strong>Taxes</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company is a North Carolina corporation that is treated as a corporation for federal and state income tax purposes. As of October 1, 2019, CBDI and Paw CBD were wholly owned subsidiaries and are disregarded entities for tax purposes and their entire share of taxable income or loss is included in the tax return of the Company and as of March 15, 2021, Therapeutics is also a wholly owned subsidiary and is a disregarded entity for tax purposes and its entire share of taxable income or loss is included in the tax return of the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for income taxes pursuant to the provisions of the <em>Accounting for Income Taxes </em>topic of the FASB ASC 740 which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company uses the inside basis approach to determine deferred tax assets and liabilities associated with its investment in a consolidated pass-through entity. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">US GAAP requires management to evaluate tax positions taken by the Company and recognize a tax liability (or asset) if the Company has taken an uncertain tax position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has analyzed the tax positions taken by the Company, and has concluded that as of September 30, 2021 and 2020, there were no uncertain tax positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the consolidated financial statements.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Concentrations</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 for substantially all depository accounts. The Company from time to time may have amounts on deposit in excess of the insured limits. The Company had a $23,508,953 uninsured balance at September 30, 2021 and a $14,287,810 uninsured balance at September 30, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not have any customers that represented a significant amount of our sales for the year ended September 30, 2021.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Stock-Based Compensation</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company accounts for its stock compensation under the ASC 718-10-30, <em>Compensation - Stock Compensation </em>using the fair value-based method. Under this method, compensation cost is measured at the grant date based on the value of the award and is recognized over the service period, which is usually the vesting period. This guidance establishes standards for the accounting for transactions in which an entity exchanges its equity instruments for goods or services. It also addresses transactions in which an entity incurs liabilities in exchange for goods or services that are based on the fair value of the entity's equity instruments or that may be settled by the issuance of those equity instruments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company uses the Black-Scholes model for measuring the fair value of options and warrants. The stock based fair value compensation is determined as of the date of the grant or the date at which the performance of the services is completed (measurement date) and is recognized over the vesting periods. The Company recognizes forfeitures when they occur.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>Earnings</strong><strong> </strong><strong>(Loss) Per Share</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company uses ASC 260-10, <em>Earnings Per Share </em>for calculating the basic and diluted income (loss) per share. The Company computes basic income (loss) per share by dividing net income (loss) and net income (loss) attributable to common shareholders, after deducting preferred stock dividends, by the weighted average number of common shares outstanding. Common equivalent shares are excluded from the computation of net loss per share if their effect is anti-dilutive.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"><strong>New</strong><strong> </strong><strong>Accounting</strong><strong> </strong><strong>Standards</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In August 2018, the FASB issued ASU No. 2018-13, <em>Fair Value Measurement (Topic 820). </em>The ASU modifies, removes, and adds several disclosure requirements on fair value measurements in Topic 820, Fair Value Measurement. The ASU 2018-13 is effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The amendments on changes in unrealized gains and losses, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively for only the most recent interim or annual period presented in the initial fiscal year of adoption. All other amendments should be applied retrospectively to all periods presented upon their effective date. The Company adopted ASU 2018-13 on October 1, 2020. The adoption of this standard had no material impact on the Company's consolidated financial statements and disclosures.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In December 2019, the FASB issued ASU 2019-12, Income Taxes, Simplifying the Accounting for Income Taxes (Topic 740). The ASU eliminates certain exceptions to the guidance in Accounting Standards Codification (ASC or Codification) 740 related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The guidance also clarifies that single-member limited liability companies and similar disregarded entities that are not subject to income tax are not required to recognize an allocation of consolidated income tax expense in their separate financial statements, but they could elect to do so. ASU 2019-12 is effective for fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company is currently in the process of evaluating the impact of this standard update.</p>
CY2021	ycbd	Organization And Nature Of Businesspolicytextblock OrganizationAndNatureOfBusinesspolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">cbdMD, Inc. ("cbdMD", "we", "us", “our”, or the “Company”) is a North Carolina corporation formed on March 17, 2015 as Level Beauty Group, Inc. In November 2016 we changed the name of the Company to Level Brands, Inc. and on May 1, 2019 we changed the name of our Company to cbdMD, Inc. We operate from our offices located in Charlotte, North Carolina. Our fiscal year end is established as September 30.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On December 20, 2018 (the “Closing Date”), the Company, and its newly organized wholly owned subsidiaries AcqCo, LLC and cbdMD LLC (“CBDI”), completed a two-step merger (the “Mergers”) with Cure Based Development, LLC, a Nevada limited liability company (“Cure Based Development”). Upon completion of the Mergers, CBDI survived and operates the prior business of Cure Based Development. As consideration for the Mergers, the Company had a contractual obligation, after approval by our shareholders, to issue 15,250,000 shares of our common stock to the members of Cure Based Development, of which unrestricted voting rights to 8,750,000 of the shares vest over a five-year period and are subject to a voting proxy agreement, as well as to issue another 15,250,000 shares of our common stock (the “Earnout Shares”) in the future upon certain earnout goals being achieved within five years from the closing of the Mergers. The Company’s shareholders approved the issuance of the 15,250,000 shares of common stock in April 2019 and these shares were issued to members of Cure Based Development on April 19, 2019. In April 2019, our shareholders also approved the possible issuance of the Earnout Shares. The first marking period for the earnout was December 31, 2019 and based on measurement criteria, 5,127,792 Earnout Shares had been earned and were issued on February 27, 2020. The sole member of Cure Based Development at the closing of the Mergers was CBD Holding LLC (“CBDH”). In February 2020, in connection with its liquidation, CBDH distributed the rights to the Earnout Shares (the “Earnout Rights”) to its members based upon the members’ pro pro-rata ownership interest in CBDH. Members of CBDH at the time of its liquidation and this distribution included affiliates of Martin A. Sumichrast and R. Scott Coffman, directors and executive officers of cbdMD. A second marking period for the earnout ended December 31, 2020 and based on measurement criteria an additional 3,348,520 Earnout Shares had been earned and were issued on March 8, 2021. The first quarter of the third marking period ended on March 31, 2021 and based on the measurement criteria an additional 562,278 Earnout Shares had been earned and issued in May of 2021. The second quarter of the third marking period ended on June 30, 2021 and based on the measurement criteria an additional 503,275 Earnout Shares had been earned and issued in August of 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company owns and operates the nationally recognized CBD (cannabidiol) brands cbdMD, Paw CBD and cbdMD Botanicals. The Company sources cannabinoids, including CBD, which are extracted from non-GMO hemp grown on farms in the United States. CBD and other hemp-derived cannabinoids are natural substances produced from the hemp plant and the products manufactured by the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">In the third quarter of fiscal 2019 cbdMD launched its new CBD pet brand, Paw CBD. Following the initial positive response to the brand from retailers and consumers, cbdMD, Inc. organized Paw CBD, Inc. (“Paw CBD”) as a separate wholly owned subsidiary on October 22, 2019, to take advantage of its early mover status in the CBD animal health industry. On March 15, 2021 cbdMD formed a new wholly owned subsidiary, cbdMD Therapeutics, LLC (“Therapeutics”) for the purposes of isolating and quantifying the Company’s ongoing investments in science related to its existing and future products, including research and development activities for therapeutic applications.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The consolidated financial statements of cbdMD have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) and should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company’s Annual Report filed with the SEC on Form 10-K for the year ended September 30, 2020 (“2020 10-K”) as filed with the SEC on December 22, 2020. In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of consolidated financial position and the consolidated results of operations for the interim periods presented have been reflected herein.</p>
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company's consolidated financial statements have been prepared in accordance with US GAAP and requires management to make estimates and assumptions that affect amounts of assets and liabilities and disclosures of contingent assets and liabilities as of the date of the financial statements and reported amounts of revenues and expenses during the periods presented. Estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary. Significant estimates made in the accompanying consolidated financial statements include, but are not limited to, allowances for doubtful accounts, inventory valuation reserves, expected sales returns and allowances, certain assumptions related to the valuation of investments other securities, acquired intangible and long-lived assets and the recoverability of intangible and long-lived assets and income taxes, including deferred tax valuation allowances and reserves for estimated tax liabilities, contingent liability and, hence consideration for the Mergers is a material estimate. Actual results could differ from these estimates.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">On March 11, 2020, the World Health Organization declared the COVID-19 outbreak to be a global pandemic. In response to this declaration and the rapid spread of COVID-19 within the United States, federal, state and local governments throughout the country have imposed varying degrees of restriction on social and commercial activity to promote social distancing in an effort to slow the spread of the illness. We continue to monitor the waning trends on infection rates and are cautiously optimistic future impacts to the business environment will be minimal.</p>
CY2021Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3633	USD
CY2020Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	20664	USD
CY2021	ycbd	Merchant Receivable And Reservepolicytextblock MerchantReceivableAndReservepolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company primarily sells its products through the internet and has an arrangement to process customer payments with multiple third-party payment processors. The Company pay a fee between 2.5% and 5.0% of the transaction amounts processed. Pursuant to this agreement, there can be a waiting period between 2 to 5 days prior to reimbursement to the Company, as well as a calculated reserve which some payment processors hold back. Fees and reserves can change periodically with notice from the processors. At September 30, 2021, the receivable from payment processors included approximately $231,257 for the waiting period amount and is recorded as accounts receivable in the accompanying consolidated balance sheet.</p>
CY2021	ycbd	Receivable From Payment Processors ReceivableFromPaymentProcessors	231257	USD
	ycbd	Deceased In Share Value DeceasedInShareValue	222442	USD
CY2021Q3	ycbd	Contingent Liability ContingentLiability	488561	USD
CY2021Q3	ycbd	Increase Of Contingent Liability IncreaseOfContingentLiability	73561	USD
CY2021Q3	ycbd	Earnout Shares Amount EarnoutSharesAmount	416000	USD
CY2021	ycbd	Advertising And Marketing Cost AdvertisingAndMarketingCost	15835139	USD
CY2020	ycbd	Advertising And Marketing Cost AdvertisingAndMarketingCost	9946755	USD
CY2020	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	1456100	USD
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1466113	USD
CY2021	us-gaap	Revenues Revenues	44480763	USD
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents, accounts receivable, and securities.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">The Company places its cash and cash equivalents on deposit with financial institutions in the United States. The Federal Deposit Insurance Corporation (“FDIC”) covers $250,000 for substantially all depository accounts. The Company from time to time may have amounts on deposit in excess of the insured limits. The Company had a $23,508,953 uninsured balance at September 30, 2021 and a $14,287,810 uninsured balance at September 30, 2020.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Concentration of credit risk with respect to receivables is principally limited to trade receivables with corporate customers that meet specific credit policies. Management considers these customer receivables to represent normal business risk. The Company did not have any customers that represented a significant amount of our sales for the year ended September 30, 2021.</p>
CY2021	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	250000	USD
CY2021Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	23508953	USD
CY2020Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	14287810	USD
CY2021	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	546878	USD
CY2020	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-932066	USD
CY2017Q4	ycbd	Shares Received SharesReceived	1226435	shares
CY2017Q4	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	38095	shares
CY2017Q4	ycbd	Total Acquisition Shares TotalAcquisitionShares	1264530	shares
CY2021	ycbd	Total Acquisition Shares TotalAcquisitionShares	1042193	shares
CY2021	ycbd	Total Acquisition Shares Value TotalAcquisitionSharesValue	33351	USD
CY2021Q3	us-gaap	Marketable Securities MarketableSecurities	33351	USD
CY2021Q3	us-gaap	Alternative Investment AlternativeInvestment	1000000	USD
CY2019Q3	ycbd	Other Investments And Securities OtherInvestmentsAndSecurities	798538	USD
CY2020	ycbd	Change In Value Of Equity Other Comprehensive Income ChangeInValueOfEquityOtherComprehensiveIncome	-772066	USD
CY2020	ycbd	Additional Investment AdditionalInvestment	250000	USD
CY2020Q3	ycbd	Other Investments And Securities OtherInvestmentsAndSecurities	276472	USD
CY2021	ycbd	Change In Value Of Equity Other Comprehensive Income ChangeInValueOfEquityOtherComprehensiveIncome	6879	USD
CY2021	ycbd	Additional Investment AdditionalInvestment	750000	USD
CY2021Q3	ycbd	Other Investments And Securities OtherInvestmentsAndSecurities	1033351	USD
CY2021Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	3362897	USD
CY2020Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2706518	USD
CY2021Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1729176	USD
CY2020Q3	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	1982021	USD
CY2021Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	70206	USD
CY2020Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	85179	USD
CY2021Q3	ycbd	Inventory Prepaid InventoryPrepaid	551519	USD
CY2020Q3	ycbd	Inventory Prepaid InventoryPrepaid	288178	USD
CY2021Q3	us-gaap	Inventory Net InventoryNet	5573386	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	4891538	USD
CY2021	us-gaap	Inventory Write Down InventoryWriteDown	670580	USD
CY2021Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4425348	USD
CY2020Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	4096593	USD
CY2021Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1863774	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	913106	USD
CY2021Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2561574	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3183487	USD
CY2021Q1	ycbd	Restricted Common Stock Amount RestrictedCommonStockAmount	118800	USD
CY2021	us-gaap	Depreciation Depreciation	968926	USD
CY2020	us-gaap	Depreciation Depreciation	111913	USD
CY2021Q3	ycbd	Amortization Of Definite Lived Intangible Assets AmortizationOfDefiniteLivedIntangibleAssets	-48482	USD
CY2020Q3	ycbd	Amortization Of Definite Lived Intangible Assets AmortizationOfDefiniteLivedIntangibleAssets	21585000	USD
CY2021Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	23003929	USD
CY2020Q3	us-gaap	Goodwill Goodwill	54669997	USD
CY2021Q3	us-gaap	Goodwill Goodwill	56670970	USD
CY2021	ycbd	Issuance Two Tranches Shares IssuanceTwoTranchesShares	6500000	shares
CY2021	ycbd	Additional Shares AdditionalShares	15250000	shares
CY2021	ycbd	Devlopment Issuance Of Two Tranches DevlopmentIssuanceOfTwoTranches	15250000	shares
CY2021	ycbd	Unrestricted Voting Right Shares UnrestrictedVotingRightShares	8750000	shares
CY2021	ycbd	Initial Shares Issued Shares InitialSharesIssuedShares	15250000	shares
CY2021	ycbd	Initial Shares Issued Value InitialSharesIssuedValue	53215163	USD
CY2020Q1	ycbd	Earnout Shares Issued EarnoutSharesIssued	5127792	shares
CY2020Q1	ycbd	Earnout Shares Amount EarnoutSharesAmount	4620000	USD
CY2021Q1	ycbd	Earnout Shares Issued EarnoutSharesIssued	3348520	shares
CY2021Q1	ycbd	Earnout Shares Amount EarnoutSharesAmount	11271000	USD
CY2021Q2	ycbd	Earnout Shares Issued EarnoutSharesIssued	562278	shares
CY2021Q2	ycbd	Initial Shares Issued Value InitialSharesIssuedValue	522104	USD
CY2021Q2	us-gaap	Shares Issued SharesIssued	503275	shares
	ycbd	Deceased In Share Value DeceasedInShareValue	222442	USD
	ycbd	Initial Shares Issued Value InitialSharesIssuedValue	920000	USD
CY2021Q3	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	488561	USD
CY2021Q3	ycbd	Increase Of Contingent Liability IncreaseOfContingentLiability	73561	USD
CY2021Q3	ycbd	Earnout Shares Amount EarnoutSharesAmount	416000	USD
CY2021Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2021Q3	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0.001
CY2021Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	5000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	500000	shares
CY2021Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2021Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.001
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	57783340	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	52130870	shares
CY2021Q3	ycbd	Restricted Common Stock RestrictedCommonStock	503275	shares
CY2021Q3	us-gaap	Class Of Warrant Or Right Unissued ClassOfWarrantOrRightUnissued	323444	shares
CY2021Q3	ycbd	Exercise Price Of Warrant ExercisePriceOfWarrant	1.25
CY2021	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	96880	USD
CY2021	ycbd	Monthly Payment Period MonthlyPaymentPeriod	P60Y
CY2021	ycbd	Financing Rate FinancingRate	0.0701	pure
CY2021	us-gaap	Sale Leaseback Transaction Monthly Rental Payments SaleLeasebackTransactionMonthlyRentalPayments	4905	USD
CY2020Q3	ycbd	Impairment Of Assets ImpairmentOfAssets	45783	USD
CY2021Q2	ycbd	Disposal Group Including Discontinued Operation Accounts Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNet	10967	USD
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	1547133	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1159949	USD
CY2021	ycbd	Weighted Average Remaining Lease Term Operating Leases WeightedAverageRemainingLeaseTermOperatingLeases	P4Y9M25D
CY2021Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0466	pure
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1405887	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1380204	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1421610	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1372862	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6740512	USD
CY2021Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	730304	USD
CY2021Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	6010208	USD
CY2021	ycbd	Net Loss Income From Continuing Operation NetLossIncomeFromContinuingOperation	-23394889	USD
CY2021	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	2554609	USD
CY2020	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	366850	USD
CY2021	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	-25949498	USD
CY2020	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Diluted NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted	12284406	USD
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	0	USD
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Attributable To Reporting Entity IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity	-48983	USD
CY2021	ycbd	Net Income Loss From Continuing And Discontinued Operations Available To Common Stockholders Basic NetIncomeLossFromContinuingAndDiscontinuedOperationsAvailableToCommonStockholdersBasic	-25949498	USD
CY2021Q1	ycbd	Restricted Common Stock RestrictedCommonStock	27000	shares
CY2021	ycbd	Shares Used In Computing Basic Earnings Per Shares SharesUsedInComputingBasicEarningsPerShares	54938128	shares
CY2020	ycbd	Incremental Common Shares Attributable To Warrants IncrementalCommonSharesAttributableToWarrants	177910	shares
CY2020	ycbd	Incremental Common Shares Attributable To Convertible Preferred Shares IncrementalCommonSharesAttributableToConvertiblePreferredShares	833500	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	54938128	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	45171674	shares
CY2021	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.47
CY2020	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	0.28
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	0
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.47
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.28
CY2021	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.47
CY2020	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	0.28
CY2021	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2020	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	0
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.28
CY2020Q1	ycbd	Restricted Common Stock RestrictedCommonStock	5127792	shares
CY2019Q4	ycbd	Common Stock Options Granted CommonStockOptionsGranted	280000	shares
CY2020Q1	ycbd	Common Stock Options Granted CommonStockOptionsGranted	30000	shares
CY2020Q2	ycbd	Common Stock Options Granted CommonStockOptionsGranted	80000	shares
CY2020	ycbd	Option Vesting Description OptionVestingDescription	The options vest immediately have an exercise price of $2.60 per share and a term of three years
CY2020	ycbd	Common Stock Options Granted Value CommonStockOptionsGrantedValue	273000	USD
CY2015Q2	us-gaap	Debt Conversion Converted Instrument Warrants Or Options Issued1 DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1	1175000	shares
CY2021	ycbd	Increase In Shares Of Common Stock IncreaseInSharesOfCommonStock	100000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	2000000	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Contingently Issuable WeightedAverageNumberOfSharesContingentlyIssuable	5000000	shares
CY2021Q1	ycbd	Totla Number Of Shares Issued And Outstanding TotlaNumberOfSharesIssuedAndOutstanding	250000	shares
CY2021	ycbd	Unrecognized Compensation UnrecognizedCompensation	1786716	USD
CY2020	ycbd	Restricted Common Stock Shares RestrictedCommonStockShares	25000	shares
CY2020	ycbd	Restricted Common Stock Amount RestrictedCommonStockAmount	80500	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	649800	USD
CY2021	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	2264893	USD
CY2020	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	138000	USD
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	660417	shares
CY2021Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.60
CY2019	us-gaap	Payments For Restructuring PaymentsForRestructuring	4900000	USD
CY2021	ycbd	Recorded Expense RecordedExpense	971554	USD
CY2020	ycbd	Recorded Expense RecordedExpense	577034	USD
CY2021	us-gaap	Increase Decrease In Other Loans IncreaseDecreaseInOtherLoans	249100	USD
CY2020Q3	ycbd	Disposal Group Including Discontinued Operation Accounts Receivable Net DisposalGroupIncludingDiscontinuedOperationAccountsReceivableNet	447134	USD
CY2021	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	1469834	USD
CY2020	ycbd	Net Loss Income From Continuing Operation NetLossIncomeFromContinuingOperation	12651256	USD
CY2021	ycbd	Net Income Loss Continuing Operations NetIncomeLossContinuingOperations	-25949498	USD
CY2020	ycbd	Net Income Loss Continuing Operations NetIncomeLossContinuingOperations	12651256	USD
CY2021	ycbd	Net Income Loss Discontinued Operations NetIncomeLossDiscontinuedOperations	0	USD
CY2020	ycbd	Net Income Loss Discontinued Operations NetIncomeLossDiscontinuedOperations	-48983	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	12602273	USD
CY2020	ycbd	Shares Used In Computing Basic Earnings Per Shares SharesUsedInComputingBasicEarningsPerShares	44140360	shares
CY2020	ycbd	Incremental Common Shares Attributable To Options IncrementalCommonSharesAttributableToOptions	19904	shares
CY2021Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9160000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5914000	USD
CY2021Q3	ycbd	Right Of Use Liability RightOfUseLiability	1342000	USD
CY2020Q3	ycbd	Right Of Use Liability RightOfUseLiability	1594000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	716000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Capital Loss Carryforwards DeferredTaxAssetsCapitalLossCarryforwards	616000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	1000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	5000	USD
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-895000	USD
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-1345300	USD
CY2021	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-895000	USD
CY2020	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-1345300	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	895000	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1345300	USD
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.008	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	-0.011	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.015	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.031	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	-0.058	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Other EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther	0.553	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.213	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.138	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.009	pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.037	pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.119	pure
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1107000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	691000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	444000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Investments DeferredTaxAssetsInvestments	685000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	165000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Tax Deferred Expense DeferredTaxAssetsTaxDeferredExpense	370000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	16000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	20000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	52000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	60000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	43000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	42000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	13046000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9997000	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	219000	USD
CY2020Q3	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	434000	USD
CY2021Q3	ycbd	Deferred Tax Liabilities Management Fees DeferredTaxLiabilitiesManagementFees	0	USD
CY2020Q3	ycbd	Deferred Tax Liabilities Management Fees DeferredTaxLiabilitiesManagementFees	0	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	4481000	USD
CY2020Q3	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssets	4650000	USD
CY2021Q3	ycbd	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	-162000	USD
CY2020Q3	ycbd	Deferred Tax Liabilities Fixed Assets DeferredTaxLiabilitiesFixedAssets	-709000	USD
CY2021Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6116000	USD
CY2020Q3	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7313000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6930000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2684000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6930000	USD
CY2020Q3	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3579000	USD
CY2021Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	895000	USD
CY2018Q3	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	2100000	USD
CY2018Q3	ycbd	Deferred Tax Asset And Related Valuation Allowance DeferredTaxAssetAndRelatedValuationAllowance	500000	USD
CY2020Q3	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	11400000	USD
CY2020Q3	ycbd	Deferred Tax Asset And Related Valuation Allowance DeferredTaxAssetAndRelatedValuationAllowance	2700000	USD
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3351000	USD
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-97000	USD
CY2021Q3	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	40700000	USD
CY2020Q3	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	895000	USD
CY2020Q3	ycbd	Decreased Deferred Tax Liability DecreasedDeferredTaxLiability	0	USD
CY2021Q3	ycbd	Deferred Tax Benefit DeferredTaxBenefit	130000	USD
CY2021	ycbd	Deferred Tax Benefit DeferredTaxBenefit	895000	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Acquisitions StockIssuedDuringPeriodSharesAcquisitions	600000	shares
CY2021Q3	us-gaap	Escrow Deposit EscrowDeposit	200000	USD
CY2021Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	300000	shares
CY2021Q3	us-gaap	Common Stock Shares Subscribed But Unissued CommonStockSharesSubscribedButUnissued	100000	shares
CY2021Q3	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	200000	shares
CY2021Q3	ycbd	Lock Up Agreement Period LockUpAgreementPeriod	P180Y
CY2021Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	300000	shares
CY2021Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	100000	shares
CY2021Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	1064000	USD
CY2021Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	200000	shares
CY2021Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	488529	USD
CY2021Q3	ycbd	Consideration Consideration	3552529	USD
CY2021Q3	us-gaap	Security Deposit SecurityDeposit	18155	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Inventory BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory	79895	USD
CY2021Q3	us-gaap	Advances On Inventory Purchases AdvancesOnInventoryPurchases	31094	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment	5000	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Intangible Assets Other Than Goodwill BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill	3418383	USD
CY2021Q3	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets	3552529	USD

Files In Submission

Name	View Source	Status
0001654954-21-013292-index-headers.html	Edgar Link	pending
0001654954-21-013292-index.html	Edgar Link	pending
0001654954-21-013292.txt	Edgar Link	pending
0001654954-21-013292-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
ycbd-20210930.xsd	Edgar Link	pending
ycbd-20210930_cal.xml	Edgar Link	unprocessable
ycbd-20210930_def.xml	Edgar Link	unprocessable
ycbd-20210930_lab.xml	Edgar Link	unprocessable
ycbd-20210930_pre.xml	Edgar Link	unprocessable
ycbd_10k.htm	Edgar Link	pending
ycbd_10kimg17.jpg	Edgar Link	pending
ycbd_10kimg18.jpg	Edgar Link	pending
ycbd_10kimg19.jpg	Edgar Link	pending
ycbd_10kimg20.jpg	Edgar Link	pending
ycbd_10kimg21.jpg	Edgar Link	pending
ycbd_10kimg22.jpg	Edgar Link	pending
ycbd_10kimg23.jpg	Edgar Link	pending
ycbd_10k_htm.xml	Edgar Link	completed
ycbd_ex211.htm	Edgar Link	pending
ycbd_ex231.htm	Edgar Link	pending
ycbd_ex311.htm	Edgar Link	pending
ycbd_ex312.htm	Edgar Link	pending
ycbd_ex313.htm	Edgar Link	pending
ycbd_ex321.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$YCBD
cbdMD, Inc. Stock $ycbd

2021 Q3 Form 10-K Financial Statement

#000165495421013292 Filed on December 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YCBD cbdMD, Inc. Stock $ycbd

2021 Q3 Form 10-K Financial Statement

#000165495421013292 Filed on December 17, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$YCBD
cbdMD, Inc. Stock $ycbd